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Abstract
Vitamin D has been associated with reduced breast cancer risk. We studied the association of two
vitaminDreceptor(VDR)genesinglenucleotidepolymorphismsrestrictionenzymedetectingSNPof
VDR (FokIa n dBsmI) with breast cancer risk in two independent case–control studies carried out in
the same population. The modifying effect offamily history of breast cancer on this relationship was
also evaluated. The ﬁrst andsecondstudies included respectively718(255cases/463 controls)and
1596 (622 cases/974 controls) women recruited in Quebec City, Canada. FokIa n dBsmI genotypes
were assessed. Relative risks of breast cancer were estimated by multivariate logistic regression.
Compared with homozygotes for the common F allele (FF genotype), FokI ff homozygotes had a
higher breast cancer risk (study 1: oddsratio (OR)Z1.22, 95% conﬁdence interval (CI)Z0.76–1.95;
study 2: ORZ1.44, 95% CIZ1.05–1.99; and combined studies: ORZ1.33, 95% CIZ1.03–1.73).
Signiﬁcant interactions were observed between FokI and family history of breast cancer in the two
studies as well as in the combined analysis (P interactionZ0.031, 0.050 and 0.0059 respectively).
Among women without family history, odds ratios were 1.00, 1.27 (95% CIZ1.02–1.58) and 1.57
(95%CIZ1.18–2.10)respectivelyforFF,Ffandffcarriers(PtrendZ0.0013).BsmIBbCbbgenotypes
were associated with a weak non-signiﬁcant increased risk in the two studies (combined ORZ1.22,
95% CIZ0.95–1.57) without interaction with family history. Results support the idea that vitamin D,
through its signalling pathway, can affect breast cancer risk. They also suggest that variability in
observed associations between VDR FokI and breast cancer from different studies may partly be
explained by the proportion of study subjects with a family history of breast cancer.
Endocrine-Related Cancer (2008) 15 975–983
Introduction
Low-vitamin D intakes or circulating levels have been
associated with increased breast cancer risk in several
ecological (Garland et al. 1990, 1999, Grant 2002,
2003), case–control and cohort studies (Van’t Veer
et al.1 9 9 1 , Zaridze et al. 1991, Knekt et al. 1996,
Negri et al. 1996, John et al. 1999, Shin et al. 2002,
Abbas et al. 2008) although not all (Graham et al.
1991, Simard et al. 1991, Levi et al. 2001). An inverse
relationship between vitamin D/calcium intakes and
breast density has also been observed (Holmes et al.
2001, Berube et al. 2004, 2005, Colangelo et al. 2006),
as well as synchronized seasonal variations of
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breast density (Brisson et al.2 0 0 7 ). A recent
randomized controlled trial involving vitamin D
supplementation sufﬁcient to raise serum 25(OH)D
O80 nmol/l in postmenopausal women reported a
decrease in all-cancer risk including a decrease in risk
of breast cancer (Lappe et al. 2007).
In vivo and in vitro experimental studies have shown
that vitamin D inhibits cellular proliferation, induces
apoptosis and suppresses tumour growth (reviewed in
Banerjee&Chatterjee(2003)andWelsh(2004)).These
effects of vitamin D on cells are thought to be mediated
through the vitamin D receptor (VDR) that belongs to
the steroid receptorsuperfamily. The VDR isexpressed
in different tissues including normal and cancerous
mammaryepithelialcells(Wietzkeetal.2005).Several
recent studies with transgenic mice with inactivated
VDR (VDR KO mice) suggest that functional VDR
tends to reduce the amount of breast tissue structures
targeted in breast carcinogenesis. It was shown that
VDRKOmicehadheaviermammaryglands,increased
branching, greater ductal extension and higher number
of undifferentiated terminal-end bud structures during
pubertycomparedwiththewild-typemice(Zinseretal.
2002). Moreover, knocking-out VDR induces early
alveolar development during pregnancy and delays
apoptoticregressionduringinvolution(Zinser&Welsh
2004b). A dose–response relationship of the VDR gene
was demonstrated by crossing VDR KO mice with
transgenic mice carrying the activated neu oncogene
under the control of the mouse mammary tumour virus
(MMTV-neu mice) where one copy of the less efﬁcient
VDR was sufﬁcient to shorten the latency period and
increase the incidence of mammary tumour formation
(Zinser & Welsh 2004a).
The VDR harbours several known functional
polymorphisms. Some of these polymorphisms have
been analysed for potential associations with breast
cancer, including the single nucleotide polymorphisms
(SNPs) restriction enzyme detecting SNP of VDR
(FokI; rs10735810 and BsmI; rs1544410). Being
located at each end of the gene encoding VDR, they
are less likely to be in linkage disequilibrium (LD) and
are therefore good candidates for independent effects
on invasive breast cancer risk (reviewed in Uitterlinden
et al. (2004)).
Studies of VDR FokI and BsmI polymorphisms have
been conducted in different populations with mixed
results. Additional data are needed to clarify whether
these SNPs are related to breast cancer risk. Conse-
quently, we re-evaluated the associations of FokI and
BsmI polymorphisms with breast cancer risk using two
independent case–control studies carried out within the
same homogeneous Quebec population.
Materials and methods
Study 1
This case–control study has been previously described
(Demers et al. 2000, 2002). Brieﬂy, from October 1994
to March 1997, 255 women with histologically
conﬁrmed primary invasive breast carcinomas were
recruited in four hospitals of the Quebec City area
(Quebec, Canada). Hospital and population controls,
free of breast cancer, were also recruited for a total of
463. Like cases, controls had to be free of any other
cancer (except cervical intraepithelial neoplasm or
basocellular skin cancer) and, in addition, hospital
controls had to be free of any gynaecological illnesses.
Since results were essentially the same using either
hospital or population controls, the control groups were
combined for subsequent analyses. Cases and controls
were matched for age and region of residence and were
almost exclusively French Canadian. Blood samples
were obtained from cases and hospital controls after
surgery, and for cases prior to the initiation of
chemotherapy or radiotherapy. For population con-
trols, a research nurse collected blood samples during a
home visit. Information on demographic and anthro-
pometric characteristics, lifestyle habits and reproduc-
tive history was obtained from cases and controls by
telephonic interview.
VDR genotypes were assessed as follows. DNA was
extracted from whole blood with the Qiagen 96-wells
procedure and reagents (Qiagen Inc). The VDR locus
was genotyped for BsmI and FokI polymorphisms after
PCR ampliﬁcation and digestion. Primer sequences are
available upon request and PCR conditions for BsmI
have already been published (Giguere et al. 2000). The
absence of the polymorphic site (B) resulted in an
850 bp fragment while the presence of the polymorphic
site (b) resulted in 700 and 150 bp fragments (Morrison
et al.1 9 9 4 ). For the FokI polymorphism, PCR
ampliﬁcation and digestion were done as published
(Gross et al. 1996) except that overnight digestion with
1U of FokI was used to minimize partial digests. The
absence of the FokI polymorphic site (F) resulted in a
265 bp fragment and its presence (f) in 196 and 69 bp
fragments (Gross et al. 1996). The interpretation of
VDR FokIa n dBsmI genotypes was performed
without the knowledge of the status (case or control)
of study subjects; only samples for which genotypes
had been assigned with a 100% concordance between
three independent readers were included. In case of
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genotyping were reassessed independently again.
Because of limitations inthe amountof DNA available,
lack of concordance and some laboratory missing
values, genotypes of 679 and 688 participants were
obtained for FokI and BsmI respectively. We ﬁrst
analysed our data with hospital and population controls
separately and, as results were essentially the same,
control groups were merged for subsequent analysis.
Study 2
In this case–control study, 622 women with histo-
logically conﬁrmed primary invasive breast carci-
nomas were recruited from a Quebec City Breast
Centre (Centre des Maladies du Sein Desche ˆnes-Fabia)
from September 1999 to November 2001. They were
matched for age and region of residence with 974
controls recruited through voluntary response to local
newspaper advertisement and through a preventive
campaign on cardiovascular disease and osteoporosis
risk factors in women, held in different public or
working places. Controls had to be free of breast cancer
or any other cancer (except cervical intraepithelial
neoplasm or basocellular skin cancer). Details from
this cohort studied for genetic and environmental risk
factors affecting bone mineral density have already
been described elsewhere (Blanchet et al.2 0 0 3 ,
Laﬂamme et al.2 0 0 5 ). A total of 622 cases and 974
controls were genotyped in the same laboratory as in
study 1. Participants were almost exclusively French
Canadian also residing in the Quebec City metropoli-
tan area. Blood samples, information on demographic
and anthropometric characteristics, lifestyle habits and
reproductive history were obtained from cases by a
research nurse during a follow-up visit after breast
surgery and prior to the initiation of chemotherapy or
radiotherapy. For controls, blood samples and the
above information were collected at recruitment.
DNA was prepared in 96-well plates from 200 mlo f
blood using the QIAamp blood kit (Qiagen) following
the manufacturer’s recommendations. The collected
DNA was further diluted ﬁve times with a solution
10 mM TRIS–HCl (pH 7.5), containing 33.7 mMo fa n
inert ﬂuorescent dye, 6-carboxyl-X-rhodamine (ROX)
(Molecular Probes, Invitrogen). All SNPs were ana-
lysed by allele-speciﬁc PCR, primer sequences are
available upon request. For each PCR, 5 ml was used
regardless of the DNA concentration. Raw genotyping
results were analysed using software developed
in-house using VC
CC programming language (Micro-
soft) that determines genotypes directly from raw
ﬂuorescence measurements for each (normal and
mutated allele) allele-speciﬁc reaction. Ambiguous
genotypes were reanalysed by allele-speciﬁc PCR
until unambiguous results were achieved. Genotypes
were automatically linked to individual DNA samples
usingtheDNAplatebarcodeandthetwoPCRplatebar
codes (one per allele). Until now, with the use of this
method, duplicate analysis of 5000 genotypes from 15
differentSNPassaysshowedanaveragereproducibility
of 99.7% and an average rate of data rejection !1%.
Thisresultsin1585and1584genotypedparticipantsfor
FokI and BsmI respectively.
The two studies, where all participants signed an
informed consent form, were approved by the Research
Ethics Review Board of the different institutions
involved.
Statistical analysis
Unconditional logistic regression was used to estimate
relative risk (odds ratio) of breast cancer in relation to
genotypes. Before combining the two studies, hetero-
geneity was examined using the likelihood ratio test to
assess the statistical signiﬁcance of an interaction term
between study and polymorphisms. Matching variables
and those known to be breast cancer risk factors were
considered potential confounders and were included in
the models. No attempt to reach more parsimonious
models were tried in order to compare our results with
the recent and largest study done to date on these SNPs
(Chen et al. 2005). Effect modiﬁcation (departure from
odds-ratio multiplicativity) was examined by introdu-
cing an interaction term between the SNP and the risk
factor under consideration in the logistic regression
models with both factors as main effect, and tested as
above. The modifying effects were ﬁrst assessed in
study 1 and those observed in study 1 were then
retested in study 2. Only results for effect modiﬁcation
by family history of breast cancer are reported since it
is the only factor showing effect modiﬁcation in the
two studies. In order to explore possible associations
further, dose–response trend in relative risk with
increasing number of risk alleles was assessed by
treating the genotypes as a continuous variable (scored
0, 1 and 2) in the models. Such analyses were
conducted among family history subgroups, the b
coefﬁcients representing the per-allele increase in
relative risk. All statistical tests were two sided and a
nominal P value of 0.05 was considered statistically
signiﬁcant. Analyses were performed with SAS
version 8.2. Hardy–Weinberg equilibrium and the
absence of LD were evaluated using the allele
procedure of SAS version 9.1.
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The principal characteristics of women in our studies
arepresentedinTable1.Somedifferencescanbefound
between the two studies but those differences are
relatively small. For instance, women from the second
study were slightly older and somewhat less likely to
have a high parity, to be current smokers or
postmenopausal.
Associations of FokI and BsmI with invasive
breast cancer
There was no statistically signiﬁcant deviation from
the expected Hardy–Weinberg equilibrium in control
samples for both polymorphisms in both studies. We,
like others (Hayes et al. 2005, Sweeney et al. 2006),
f o u n dn oL Db e t w e e nt h e s et w op o l y m o r p h i s m s
(study 1, D0Z0.13; study 2, D0Z0.020). Minor allele
frequencies for both SNPs were similar in both studies
(allele frequencies in controls-FokI: study 1, fZ0.38;
study 2, fZ0.39 and BsmI: study 1, BZ0.42; study 2,
BZ0.39) and genotypes frequencies in these samples
from French Canadian population were similar to other
Caucasian populations (Uitterlinden et al. 2004).
FokI was associated with an increased relative risk
of breast cancer in the two studies reaching statistical
signiﬁcance in study 2 (Table 2). There was no
heterogeneity between the two studies (P heterogenei-
tyZ0.17). In the combined analysis, relative risk was
1.33 (95% CIZ1.03–1.73) for ff genotype and 1.15
(95% CIZ0.95–1.40) for Ff heterozygotes compared
with those carrying the common FF genotype.
BsmI showed little association with breast cancer risk
(Table 2) but results were similar in both studies
(P heterogeneityZ0.80) and data were combined. Odds
ratios for women who had one or two b allele were
identical (OR Z1.21; 1.23, for Bb and bb genotypes
respectively). Compared with women with the BB
genotype,thecombinationofBbandbbcarrierssuggests
an association with breast cancer risk (ORZ1.22, 95%
CIZ0.95–1.57, PZ0.12; data not shown).
Effect modiﬁcation by family history of
breast cancer
When stratifying women by family history of breast
cancer in ﬁrst-degree relatives, a higher risk associated
with FokI f allele was seen only in women reporting no
family history (Table 3). Interaction between family
history of breast cancer and FokI was statistically
signiﬁcant in both studies as well as in the combined
analysis (P interactionZ0.031, 0.050 and 0.0059
respectively). Among women without family history,
relative risks were 1.27 (95% CIZ1.02–1.58) and 1.57
(95% CIZ1.18–2.10) respectively for FokIF fa n df f
genotypes compared with women with FF genotype.
The per-allele increase in relative risk is 1.26, i.e. each
additional f multiplied the relative risk by 1.26
(bZ0.2285, PtrendZ0.0013). By contrast, among
women with a history of breast cancer, odds ratios
were slightly lower for those with f alleles (ORZ0.73,
95% CIZ0.46–1.17 for heterozygotes; ORZ0.66,
95% CIZ0.36–1.19 for homozygotes in the combined
study) but neither genotype nor trend (PtrendZ0.13)
Table 1 Characteristics of women by study
Study 1 (nZ718) Study 2 (nZ1596)
Age (years; meanGS.D.) 52.3G9.7 55.8G10.5
Age (years) at menarche
a (meanGS.D.) 12.7G1.7 12.8G1.6
Family history of breast cancer
b (%) 16.0 16.2
Body mass index (kg/m
2; meanGS.D.) 25.0G4.5 25.6G4.8
Age (years) at ﬁrst birth
c (meanGS.D.) 24.8G4.3 25.6G4.6
Parity
d (%)
Nulliparous 18.5 20.2
1–2 birth 43.9 48.3
3Cbirth 37.6 31.5
Smoking status
e (%)
Non-smoker 49.7 56.4
Former smoker 29.2 27.7
Current smoker 21.1 15.9
Postmenopausal (%) 66.8 61.1
aTwo missing values in study 2 (nZ1594).
bIn mother, sister, daughter; 13 missing values in study 1 (nZ705).
cIn parous women (study 1, nZ585; study 2, nZ1271).
dThree missing values in study 2 (nZ1593).
eSix missing values in study 2 (nZ1590).
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by family history of breast cancer was apparent for the
relationship of BsmI to breast cancer (P interac-
tionZ0.93; data not shown).
Discussion
Our results suggest that, within this almost exclusively
Caucasian population of French origin, FokI VDR
polymorphism is associated with an increased risk of
invasive breast cancer. The association of FokIi s
stronger in women without a family history of breast
cancer in ﬁrst-degree relatives. BsmI polymorphism
appears to bear only a weak relationship to breast
cancer risk, if any, in this population.
FokI and breast cancer
Seven papers have analysed the association of FokI
with breast cancer risk (Curran et al. 1999, Ingles et al.
2000, Bretherton-Watt et al. 2001, Guy et al. 2003,
2004, Chen et al. 2005, McCullough et al. 2007), three
of which are apparently emerging from the same UK
Caucasian population sample (Bretherton-Watt et al.
2001, Guy et al. 2003, 2004) and are reporting non-
signiﬁcant but generally lower relative risk of breast
cancer for the f allele carriers. Three other studies
(Curran et al. 1999, Ingles et al. 2000, McCullough
et al. 2007) did not observe any association. In the
Nurses’ Health Study (Chen et al. 2005) conducted
within US population, the ff carriers showed a
statistically signiﬁcant increase in relative risk of
breast cancer compared with women with the FF
genotype (ORZ1.34; 95% CIZ1.06–1.69), which is
consistent with our present ﬁndings (ORZ1.33; 95%
CIZ1.03–1.73). Moreover, both studies suggest that
relative risk of breast cancer increases with the
increasing dosage of the f allele. If our observed
associations are valid and causal, about 13 and 25% of
Table 2 Restriction enzyme detecting SNP of VDR (FokI and BsmI) vitamin D receptor (VDR) polymorphisms and breast cancer risk
Cases N (%) Controls N (%) Adjusted OR
a 95% CI P
b
FokI
Study 1
FF 92 (37.9) 164 (38.8) 1.0
Ff 105 (43.2) 196 (46.3) 0.96 0.67–1.37 0.83
ff 46 (18.9) 63 (14.9) 1.22 0.76–1.95 0.42
Total 243 (100) 423 (100)
Study 2
FF 198 (32.1) 353 (36.8) 1.0
Ff 306 (49.7) 451 (47.1) 1.30 1.02–1.65 0.036
ff 112 (18.2) 154 (16.1) 1.44 1.05–1.99 0.024
Total 616 (100) 958 (100)
Combined
FF 290 (33.8) 517 (37.4) 1.0
Ff 411 (47.8) 647 (46.8) 1.15 0.95–1.40 0.16
ff 158 (18.4) 217 (15.7) 1.33 1.03–1.73 0.029
Total 859 (100) 1381 (100)
BsmI
Study 1
BB 36 (15.2) 87 (19.9) 1.0
Bb 109 (46.0) 192 (43.8) 1.39 0.87–2.23 0.17
bb 92 (38.8) 159 (36.3) 1.42 0.88–2.30 0.16
Total 237 (100) 438 (100)
Study 2
BB 80 (13.0) 140 (14.7) 1.0
Bb 300 (48.6) 461 (48.2) 1.17 0.84–1.63 0.35
bb 237 (38.4) 355 (37.1) 1.15 0.82–1.62 0.41
Total 617 (100) 956 (100)
Combined
BB 116 (13.6) 227 (16.3) 1.0
Bb 409 (47.9) 653 (46.8) 1.21 0.93–1.58 0.16
bb 329 (38.5) 514 (36.9) 1.23 0.94–1.62 0.13
Total 854 (100) 1394 (100)
aORs are adjusted for age, age at menarche, family history of breast cancer in ﬁrst-degree relatives, region (except for the combined
study), body mass index, parity/age at ﬁrst birth, tobacco use, menopausal status and study (only for the combined study).
bP values for comparisons of at-risk genotypes with reference homozygote genotypes.
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would be attributableto theirrespectiveFokI genotypes.
The FokI polymorphism is located at exon 2 start
codon of the VDR gene. Individuals designated F have
VDR proteins missing three amino acids (424 amino
acids) and those designated f have longer VDR proteins
(427 amino acids) that have been shown to be
functionally less efﬁcient (reviewed in Uitterlinden
et al. (2004)).
Since f allele results in a less efﬁcient VDR, the
increase in breast cancer incidence associated with f
allele could possibly be overturned, or at least reduced,
by raising vitamin D levels, for instance through
vitamin D supplementation. Interaction between VDR
FokI SNP and vitamin D has been recently observed
for prostate cancer (Li et al. 2007). Carriers of ff
genotype with less than median circulating vitamin D
were at higher risk of total and aggressive cancers
while exposure to higher than median vitamin D was
able to completely overcome those risks.
The increase in relative risk of breast cancer with an
increasing number of f alleles was signiﬁcant among
women without family history of breast cancer in ﬁrst-
degree relatives. Actually, among women declaring a
family history of breast cancer in ﬁrst-degree relatives,
relative risk of breast cancer decreased slightly with the
number of f alleles. This effect modiﬁcation by family
history on the relationship of f allele to breast cancer
risk was observed in our two case–control studies
and, in both of these, interaction was statistically
signiﬁcant. Such a modifying effect, if conﬁrmed,
might help to explain the apparent contradictions
among results found in the literature since the strength
of the relationship of the f allele to breast cancer risk
seen in a given study would tend to vary according to
the proportion of the study group that has a family
history of breast cancer.
BsmI and breast cancer
BsmI polymorphism is located in intron 8 of the VDR
gene and is unlikely to affect VDR function. However,
this polymorphism is in strong LD with the poly(A)
microsatellite located in the 30 untranslated region
(UTR) that might inﬂuence either VDR mRNA
stability or VDR translational activity (reviewed in
Uitterlinden et al. (2004)). The variable-length poly(A)
sequence has been associated with breast cancer and
also with bone mineral density and height.
Eleven studies assessed BsmI association with breast
cancer risk (Ruggiero et al. 1998, Ingles et al. 2000,
Bretherton-Watt et al. 2001, Hou et al. 2002, Buyru
et al. 2003, Guy et al. 2003, 2004, Heﬂer et al. 2004,
Chen et al. 2005, Lowe et al. 2005, McCullough et al.
2007). Only two studies reported a signiﬁcant
increased risk for the BB carriers and they were
respectively from a Hispanic (Ingles et al. 2000) and a
Taiwanese population (Hou et al. 2002) with allele
frequencies considerably different from those seen in
Caucasian populations. Studies among Caucasian
women are showing mixed results. Some earlier and
Table 3 Restriction enzyme detecting SNP of VDR (FokI) vitamin D receptor (VDR) polymorphism and breast cancer risk by family
history of breast cancer
With family history Without family history
FokI
Cases/
controls OR
a 95% CI P
b
Cases/
controls OR
a 95% CI P
b P for interaction
Study 1
FF 25/18 1.0 67/146 1.0
Ff 21/26 0.56 0.24–1.32 0.18 84/170 1.01 0.67–1.51 0.98
ff 10/15 0.41 0.15–1.16 0.14 36/48 1.51 0.89–2.58 0.13 0.031
Total 56/59 187/364
Study 2
FF 47/47 1.0 151/306 1.0
Ff 54/62 0.79 0.44–1.40 0.41 252/389 1.44 1.10–1.88 0.0073
ff 19/24 0.78 0.37–1.69 0.54 93/130 1.65 1.16–2.35 0.0053 0.050
Total 120/133 496/825
Combined
FF 72/65 1.0 218/452 1.0
Ff 75/88 0.73 0.46–1.17 0.19 336/559 1.27 1.02–1.58 0.030
ff 29/39 0.66 0.36–1.19 0.17 129/178 1.57 1.18–2.10 0.0020 0.0059
Total 176/192 683/1189
aORs are adjusted for age, age at menarche, region (except in the combined study), body mass index, parity/age at ﬁrst birth,
tobacco use, menopausal status and study (only in the combined study).
bP values for comparisons of at-risk genotypes with reference homozygote genotypes.
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2003, 2004, Lowe et al. 2005) reported signiﬁcant
increased risk for bb carriers while larger and more
recent ones (Heﬂer et al. 2004, Chen et al. 2005) did
not conﬁrm previous associations. Although our BsmI
results from both studies are non-signiﬁcant, they are
nevertheless showing the same pattern, perhaps
suggesting a lack of statistical power. Our combined
analysis suggest that if an actual increased risk exists
for BsmI Bbor bb carriers, this increase wouldlikely be
small (ORZ1.22, 95% CIZ0.95–1.57) although,
according to the upper limit of the conﬁdence interval,
a moderately increased risk (i.e. RR of about 1.5)
cannot be excluded. Recently, the largest genome-wide
association study on sporadic postmenopausal breast
cancer has showed a signiﬁcant association (PZ0.013)
of the same order of magnitude with BsmI (rs1544410;
see http://cgems.cancer.gov/data/ (Hunter et al. 2007)).
Limitations
This study faces the usual limitations of association
studies between genetic markers and diseases. Since
we analysed two polymorphisms chosen on the basis of
previous ﬁndings and found the same association
patterns in two independent studies, we believe that
type 1 errors are less likely to explain our ﬁndings.
Population stratiﬁcation is the major source of
confounding in this type of study (Khoury et al.
1993, Rothman & Greenland 1998) although this
problem might not be as important as anticipated in
North American Caucasian populations (Rothman
et al. 2001, Wacholder et al. 2002, Cardon & Palmer
2003). In our two studies, the majority of women
resided in the Quebec City area, where 95% of its
800 000 residents are Caucasians of French origin. We
do not expect strong differences in allele frequencies
within this area. Thus, it seems unlikely that our results
could be due to population stratiﬁcation. Non-
differential misclassiﬁcation bias from laboratory
measurements is possible for genetic markers as for
other analytical variables. Although in the absence
of Hardy–Weinberg disequilibrium this is unlikely, a
special case of non-differential misclassiﬁcation
between BsmI marker allele and an unmeasured
putative susceptibility allele is also possible. This
type of misclassiﬁcation results from the fact that BsmI
marker, being intronic, needs to be in LD with a yet
unknown functional allele in order to explain a possible
association between BsmI polymorphism and breast
cancer. As LD between the BsmI marker and an
unknown functional allele is not likely to be complete,
some non-differential misclassiﬁcation can occur
(Khoury et al. 1993). A haplotype analysis around
the 30UTR region would help reduce this problem. The
FokI polymorphism, being functional and not in LD
with any other VDR polymorphism (reviewed in
Uitterlinden et al. (2004)), is less likely to be affected
by this type of misclassiﬁcation. Of note, these two
types of misclassiﬁcation bias would tend to under-
estimate true relative risks.
Conclusion
In our study population of French Canadian origin, an
increasingnumberofFokI fallele,whichwaspreviously
shown to result in a decreased efﬁciency of VDR, was
associated with a signiﬁcant increase in relative risk in a
dose–response manner compatible with a co-dominant
(additive) effect. This association was seen only in
women without a family history of breast cancer in ﬁrst-
degree relatives. The study of BsmI polymorphism,
however, suggested a more subtle b allele dominant risk
effect, regardless offamily history.
Overall, these results on VDR polymorphisms
support the growing evidence for a protective effect
of vitamin D on the risk of breast cancer. Future studies
on the relationship of VDR FokI polymorphism and
breast cancer should take into account the potential
modifying effect of family history of breast cancer in
ﬁrst-degree relatives.
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